TY - JOUR
T1 - Effects of sex and remifentanil dose on rats' acquisition of responding for a remifentanil-conditioned reinforcer
AU - Bertz, Jeremiah W.
AU - Jackson, Emily L.
AU - Barron, Davina R.
AU - Woods, James H.
N1 - Funding Information:
This research was supported by the National Institute on Drug Abuse under grants T32DA07268 and R01DA024897 and by the University of Michigan Undergraduate Research Opportunity Program. A preliminary report of these datawas given at the 2014 meeting of the College on Problems of Drug Dependence (San Juan, Puerto Rico).
Publisher Copyright:
© Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016/4
Y1 - 2016/4
N2 - Opioid-conditioned reinforcement is thought to exacerbate opioid abuse and dependence. Sex/gender can influence opioid abuse behaviors, but the effects of sex/gender on opioid-conditioned reinforcement, specifically, are unclear. In this study, we compared new-response acquisition with opioid-conditioned reinforcement in male and female rats. First, separate groups received response-independent remifentanil injections (0.0-32.0 μg/kg, intravenous) and presentations of a light-noise stimulus. In the experimental groups, injections and stimulus presentations always cooccurred [paired Pavlovian conditioning (PAV)]; in the control groups, the two occurred independently of each other (random PAV). Next, in the instrumental acquisition (ACQ) sessions, two novel nose-poke manipulanda were introduced. All animals (regardless of sex, dose, and PAV type) could respond in the active nose-poke, which produced the stimulus alone, or in the inactive nose-poke. Both males and females dose-dependently acquired nosepoke responding (active>inactive) after paired PAV, but not after random PAV. Therefore, the stimulus was a conditioned reinforcer. We identified three sex differences. First, only females acquired responding after paired PAV with 32.0 μg/kg remifentanil. Second, using a progressive ratio schedule for ACQ, both sexes acquired responding, but females made significantly more active responses. Third, when a single session of PAV was conducted, only males acquired responding. Thus, rats' sex interacts with pharmacological and environmental factors to determine opioid-conditioned reinforcement.
AB - Opioid-conditioned reinforcement is thought to exacerbate opioid abuse and dependence. Sex/gender can influence opioid abuse behaviors, but the effects of sex/gender on opioid-conditioned reinforcement, specifically, are unclear. In this study, we compared new-response acquisition with opioid-conditioned reinforcement in male and female rats. First, separate groups received response-independent remifentanil injections (0.0-32.0 μg/kg, intravenous) and presentations of a light-noise stimulus. In the experimental groups, injections and stimulus presentations always cooccurred [paired Pavlovian conditioning (PAV)]; in the control groups, the two occurred independently of each other (random PAV). Next, in the instrumental acquisition (ACQ) sessions, two novel nose-poke manipulanda were introduced. All animals (regardless of sex, dose, and PAV type) could respond in the active nose-poke, which produced the stimulus alone, or in the inactive nose-poke. Both males and females dose-dependently acquired nosepoke responding (active>inactive) after paired PAV, but not after random PAV. Therefore, the stimulus was a conditioned reinforcer. We identified three sex differences. First, only females acquired responding after paired PAV with 32.0 μg/kg remifentanil. Second, using a progressive ratio schedule for ACQ, both sexes acquired responding, but females made significantly more active responses. Third, when a single session of PAV was conducted, only males acquired responding. Thus, rats' sex interacts with pharmacological and environmental factors to determine opioid-conditioned reinforcement.
KW - Conditioned reinforcement
KW - Cues
KW - Drug abuse
KW - New-response acquisition
KW - Opioid
KW - Pavlovian conditioning
KW - Rat
KW - Sex difference
UR - http://www.scopus.com/inward/record.url?scp=84962496213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962496213&partnerID=8YFLogxK
U2 - 10.1097/FBP.0000000000000205
DO - 10.1097/FBP.0000000000000205
M3 - Article
C2 - 26580131
AN - SCOPUS:84962496213
SN - 0955-8810
VL - 27
SP - 137
EP - 147
JO - Behavioural Pharmacology
JF - Behavioural Pharmacology
IS - 2-3
ER -